Consider what the Republican coalition just told us about the Food and Drug Administration. The agency approves the drugs that treat cancer, clears the vaccines that keep measles out of kindergartens, and polices the food supply. For months it has been run by an acting commissioner. The nominee to fix that was pulled a day before her committee vote. The reason in dispute is not competence. It is whether she would pledge to restrict one pill.
Heidi Overton was no moderate. She is a Trump White House adviser and a loyal soldier. Her offense, apparently, was insufficient zeal. SBA Pro-Life America didn't hide what it wanted. It wants the next nominee to commit in advance to ending mail-order distribution of abortion medication and to rewriting how the FDA reviews those drugs' safety. Note the order of operations: the conclusion first, the review afterward.
That is not how a drug regulator is supposed to work, and the people demanding it know it. Mifepristone has been on the market for a quarter century. It has been studied, reviewed and used by millions of Americans, and its safety record is better than that of many drugs sold over the counter. If the FDA's scientists conclude something new, let them show their work. But a lobbying group demanding a promised result from a nominee before she is confirmed is demanding a verdict before the trial. Call it what it is: using the regulatory apparatus as a political weapon and dressing it as safety.
The stakes reach well beyond abortion. Medication abortion now accounts for a majority of abortions in the United States, and telehealth has become a lifeline for women in states that have banned the procedure or have no clinic within hundreds of miles. Ending mail-order access would do what the Right has not managed through legislation: impose a de facto national restriction through an agency, without a vote in Congress and without any real public mandate. It would hit hardest the women who can least afford to travel: the rural, the poor, the young.
The tell is what Overton said at her hearing. She called the MMR vaccine safe and effective. That is a sentence no one should need courage to utter, yet it now counts as a point of friction in a party whose health secretary has spent a career casting doubt on vaccines. The FDA's credibility rests on the idea that its judgments follow evidence. Each time a nominee must be screened for fealty on one side or the other, that idea erodes. People stop asking whether a decision is right and start asking who won.
The obvious rejoinder is that this is just democracy. Senators answer to voters, anti-abortion voters are a core part of the Republican base, and advice and consent has always meant politics. True. But the Senate's constitutional role is to vet nominees, not to extract private promises about the outcome of scientific reviews. And Chairman Bill Cassidy says the nomination had a path forward and that the White House chose to withdraw her instead of giving the assurances those senators wanted. If he is right, this was a choice. The administration decided it would rather leave the nation's drug regulator leaderless than risk offending one advocacy group.
Cassidy deserves a hard look too. He is a physician who says he cares about vaccines and science, yet he helped install the health secretary who made those worries necessary. He cannot keep serving as the party's conscience on public health while enabling the people who keep testing it.
Democrats shouldn't just watch this. Every confirmation fight over health policy should be forced into one question: will you let scientists decide, or will you take dictation? Americans can live with disagreement about abortion. They should not accept a regulator whose conclusions were promised to a political donor class before the evidence came in.
How it may affect me
If you get medication abortion through telehealth or mail, watch the FDA's review of mifepristone's safety rules, because the next commissioner could be pressured to restrict that access. More broadly, an acting leader at the FDA can slow major decisions on drug approvals and food safety.


